

MO HEALTHNET DRUG UTILIZATION REVIEW BOARD

October 18, 2017

Department of Natural Resources, La Charrette/Nightengale Conference Rm, Jefferson City MO

DUR BOARD MEMBERS PRESENT

Susan Abdel-Rahman, Pharm D – Board Chair
Charlene Heyde, RPh
Sandra Bollinger, Pharm D
Glenn Talboy, MD
Stacy Mangum, Pharm D
Ginger Nicol, MD, CEDS

DUR BOARD MEMBER GUESTS

Nick Legrand, STLCOP Student
Chelsea Clark, STLCOP Student

DUR BOARD MEMBERS ABSENT

Jennifer Passanise, FNP
Kenneth Haller, MD
Randy Beckner, Pharm D

OTHERS IN ATTENDANCE

Mike Lafond, AbbVie
Ashley Polce, AbbVie
Evan Rushing, Alkermes
Lisa Tootle, Bristol-Myers Squibb
Jessica Petrie, Dermax Center
Brent DePriest, GlaxoSmithKline
Brian Strickland, Gilead
Steve Naert, Lilly
Matthew Stafford, Merck
Terry McCurren, Otsuka

Phillip King, Pfizer
John Ammani, SLV
Heather Maruska, United Healthcare
Eric Gardner, Vertex
Jill Nitz, Wipro
Chelsea Pendleton, Wipro

MHD STAFF PRESENT

Mark Roaseau, RPh, Clinical Pharmacist
Frances (Franki) Moseley, Administrative Office Support Assistant
Elizabeth Short, Medicaid Specialist
Jenna McTeer, RN, Clinical Management
Lisa Smith, Program Development Specialist
Mitch Ruth, Fiscal Unit Manager

CONTRACTED STAFF PRESENT

Joshua Moore, Pharm D, Conduent
Katie Wilbers, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Janelle Sheen, Pharm D, Conduent
Richard Pope, Pharm D, Magellan

Welcome, Introductions and Opening Remarks	Susan Abdel-Rahman, Pharm D, called the meeting to order. Mark Roaseau, RPh, facilitated the meeting on behalf of the MO HealthNet Division (MHD).
Minutes Review and Approval	Minutes of the July 2017 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes)
Pharmacy Program/Budget Update	Mitch Ruth, Fiscal Unit Manager, presented a brief power point presentation. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking and State Opioid activities.
Old Business Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included the PDL decisions to be implemented January 2018. Pending ratification, PDL decisions from September/October will be implemented January 2018. Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Drug Review	Mark Roaseau, reviewed the new drug products that were identified for the quarter April, May, and June 2017, the recommended status within the clinical program. <ul style="list-style-type: none"> • Discussion - A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet, along with the Drug Prior Authorization Committee's actions/decisions. • Decision - The listing and recommendations were approved as part of a block vote by the DUR Board (See Roll Call Votes).
Clinical Edits	
Short-Acting Opioids Clinical Edits	<ul style="list-style-type: none"> • Discussion – Dr. Luke Boehmer, Conduent, reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
Opiate Dependence Agents PDL (Approval Criteria)	<ul style="list-style-type: none"> • Discussion – Dr. Luke Boehmer, Conduent, reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
Emflaza® Clinical Edit	<ul style="list-style-type: none"> • Discussion – Dr. Mark Roaseau reviewed the criteria document. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
Tymlos®/Forteo® Clinical Edit	<ul style="list-style-type: none"> • Discussion – Dr. Mark Roaseau reviewed the criteria document, and recommended updates to approval and denial criteria. • Public Hearing – No comments entered. • Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)

Bidil® Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Dr. Mark Roaseau reviewed the criteria document, and recommended updates to approval and denial criteria. ● Public Hearing – No comments entered. ● Decision – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)
Preferred Drug List (PDL) Annual Review	
Ace Inhibitor Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
ACE Inhibitors/Calcium Channel Blocker Combination Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
ACE Inhibitors/Diuretic Combination Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Angiotensin Receptor Blocker Agents(ARB's)	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Angiotensin Receptor Blocker/Diuretic Combination Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)
Angiotensin Receptor/Calcium Channel Blocker Combination Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Anticoagulant Agents: Oral and Subcutaneous	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)
Antiplatelet Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Beta Adrenergic Blockers and Diuretic Combination Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes)

Calcium Channel Blocker Agents (Non-Dihydropyridines)	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Calcium Channel Blocker Agents (Non-Dihydropyridines)	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Direct Renin Inhibitors and Combination Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Hepatitis C Therapy: Direct-Acting Antiviral Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. Mark Roaseau indicated that the Missouri HealthNet Division plans to implement this edit on November 1, 2017. (See Roll Call Votes).
Homozygous Familial Hypercholesterolemia Products	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Lipotropic Agents: Niacin and Combination Preparations	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Lipotropic agents: Statins (HMG Co-A Reductase Inhibitors) and Statin Combination Products	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Proton Pump Inhibitor Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Pulmonary Hypertension Agents: Inhaled/Injectable	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Pulmonary Hypertension Agents: Oral	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Sympatholytic Antihypertensive Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).

Triglyceride Lowering Agents	<ul style="list-style-type: none"> ● Discussion – Mark Roaseau presented the criteria document, reviewing preferred and non-preferred agents. ● Decision – This edit was accepted and added to the block vote. (See Roll Call Votes).
Call Center Statistics Clinical Edit Summary Report	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were also provided. Dr. Luke Boehmer presented updated Call Center Statistics for the Short Acting Single Agent Opioids and Short Acting Combination Opioids. Dr. Boehmer also presented utilization data documenting the impact of the edit changes on morphine equivalents and units dispensed.
Conduent Update	Dr. Luke Boehmer discussed the Call Center Statistics for the Short Acting Single Agent Opioids, Short Acting Combination Opioids, and Long Acting Opioids both Pre-Implementation of the last dosing reductions and Post-implementation of the last dosage reductions. Dr. Boehmer discussed the Spend PMPM and Claims PMPM for the Short Acting Single Agent Opioids, Short Acting Combination Opioids, and Long Acting Opioids. Dr. Boehmer discussed the overall Claims trends for Opioids since 2009 and the trend of patients taking over the recommended max dose since 2009. Dr. Boehmer discussed the Respiratory Distress Incidence among patients taking Short Acting Single Agent Opioids, Short Acting Combo Opioids, Long Acting Opioids, and the Opioid Dependence Agents. Dr. Boehmer looked at data for patients who had an incidence of Respiratory Distress after receiving an Opioid. Dr. Boehmer also looked at data for patients who had another respiratory disease diagnosis along with the respiratory distress diagnosis. Dr. Luke Boehmer discussed last the FFS Overdose Incidence Report year over year since 2013. Dr. Luke Boehmer discussed the number of patients that had an ER visit due to an Overdose and the number of patients that were admitted to inpatient status as a result of an overdose.
Drug Utilization Review Activities	Dr. Katie Wilbers presented to the board the changes to the patient hand out for the Benzodiazepine Mailing. Dr. Katie Wilbers proposed a new DUR intervention for Opioids in Pregnancy and for Stroke.
Preferred Drug List Announcement	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf
Program Utilization: Top 25 Drugs Summary	Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 nd , 3 rd , & 4th quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
Adjourn	Sandra Bollinger, Pharm D, made a motion to move to close the meeting under Section 610.021 (5),(14) to go into Executive Session for the sole purpose of discussing individual participant specific medical information. (See attached roll call vote). At the conclusion of this discussion the meeting was adjourned entertaining no further business, actions, or motions. (See attached roll call vote). The next DUR Board meeting is scheduled for January 17, 2018, at the Missouri Coalition for Community Behavioral Healthcare, Lower Level CEO Room, 221 Metro Drive , Jefferson City MO.

Roll Call Votes – October 18, 2017

MEMBERS	MEETING MINUTES	NEW DRUGS	ALL RECOMMENDATIONS BLOCK VOTE	CLOSED SESSION PURSUANT TO SECTION 610.021 SUBSECTION (14), (5)	ADJOURN EXECUTIVE SESSION
Susan Abdel-Rahman, Pharm D	Y	Y	Y	Y	Y
Charlene Heyde, RPh	Y	S, Y	Y	Y	S, Y
Sandra Bollinger, Pharm D	M, Y	M, Y	Y	Y	M, Y
Kenneth Haller, MD	A	A	A	A	A
Glenn Talboy, MD	S, Y	Y	M, Y	M, Y	Y
Jennifer Passanise, FNP	A	A	A	A	A
Stacy Mangum, Pharm D	Y	Y	Y	Y	Y
Ginger Nicol, MD, CEDS	Y	Y	S, Y	S, Y	Y
Randy Beckner, Pharm D	A	A	A	A	A

M - motion to vote
S - second to vote
Y - yes to the vote
N – no to the vote
A - absent

EXECUTIVE SESSION
October 18, 2017

DUR BOARD MEMBERS PRESENT

Susan Abdel-Rahman, Pharm D – Board Chair
Charlene Heyde, RPh
Sandra Bollinger, Pharm D
Glenn Talboy, MD
Stacy Mangum, Pharm D
Ginger Nicol, MD, CEDS

DUR BOARD MEMBER GUESTS

Nick Legrand, STLCOP Student
Chelsea Clark, STLCOP Student

DUR BOARD MEMBERS ABSENT

Jennifer Passanise, FNP
Kenneth Haller, MD
Randy Beckner, Pharm D

MHD STAFF PRESENT

Mark Roaseau, RPh, Clinical Pharmacist
Frances (Franki) Moseley, Administrative Office Support Assistant
Elizabeth Short, Medicaid Specialist
Jenna McTeer, RN, Clinical Management
Lisa Smith, Program Development Specialist
Mitch Ruth, Fiscal Unit Manager

CONTRACTED STAFF PRESENT

Joshua Moore, Pharm D, Conduent
Katie Wilbers, Pharm D, Conduent
Luke Boehmer, Pharm D, Conduent
Janelle Sheen, Pharm D, Conduent
Richard Pope, Pharm D, Magellan

Minutes Review	There were no July minutes for the Executive Session to be approved as submitted.
Case Reviews	One Case for Review
Adjourn	Executive session